Introduction
============

Urinary cancers, including kidney cancer, prostate cancer and bladder cancer, are common types of malignancies worldwide.[@b1-ott-9-1499] For example, prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males, accounting for 14% of the total new cancer cases and 6% of the total cancer deaths in males in 2008.[@b1-ott-9-1499] Bladder cancer is the seventh most common cancer among men, with \~297,300 new incident cases per year in the world.[@b1-ott-9-1499] The estimated probability of developing urinary cancers is based on the average experience of the general population and may over- or underestimate individual risk because of differences in exposure, medical history, and/or genetic susceptibility.[@b2-ott-9-1499]

DNA repair genes play a major role in the DNA mismatch repair pathway, which includes base excision repair (BER), nucleotide excision repair, mismatch repair, and double strand break repair.[@b3-ott-9-1499] Genetic variations in genes involved in DNA repair would confer susceptibility to the tumor and would be associated to disease aggressiveness through the alteration of DNA repair pathways.[@b4-ott-9-1499] Among them, BER pathway is responsible for repairing small lesions such as oxidative damage, alkylation, or methylation.[@b5-ott-9-1499] This pathway is a multistep process that requires the activity of several proteins.[@b6-ott-9-1499] Apurinic/apyrimidinic endonuclease 1 (APE1, also known as APE, APEX, HAP1, and REF-1) is a multifunctional protein that plays a central role in the BER pathway through hydrolyzing the phosphodiester backbone immediately 5′ to the AP site.[@b5-ott-9-1499],[@b7-ott-9-1499] APE1 can act as a 3′-phosphodiesterase to initiate the repair of 3′-blocking damage at DNA single-strand breaks, which are produced either directly by reactive oxygen species or indirectly through the enzymatic removal of damaged bases.[@b8-ott-9-1499],[@b9-ott-9-1499] It also acts as a transcriptional coactivator for numerous transcription factors (AP-1, p53, Pax-5, and TTF-1) involved in cancer development.[@b10-ott-9-1499]

The human *APE1* gene (2.6 kb in size) is localized to chromosome14 q11.2-12 and consists of four introns and five exons.[@b11-ott-9-1499],[@b12-ott-9-1499] A total of 18 polymorphisms in *APE1* have been identified.[@b13-ott-9-1499] But the most extensively studied polymorphism is a T to G transversion, Asp148Glu (rs1130409 and T1349G). It was reported that the Glu was associated with an increased mitotic delay after exposure to ionizing radiation.[@b13-ott-9-1499],[@b14-ott-9-1499] Functional studies on *APE1* Asp148Glu suggested that the Glu may alter endonuclease and DNA-binding activity, reduce the ability to communicate with other BER proteins, and decrease the capacity to repair DNA oxidative damage.[@b15-ott-9-1499] In the study on X-ray exposure to lymphocytes and polymorphisms of DNA repair genes on chromosome aberrations, samples from individuals with the Asp/Glu or Glu/Glu genotype showed higher levels of damage with regard to all the studied measures, including aberrant cells, chromatid breaks, chromatid exchanges, deletions, and dicentrics.[@b16-ott-9-1499] Although numerous epidemiological studies have been conducted to explore the association between *APE1* Asp148Glu and the risk of urinary cancers,[@b17-ott-9-1499]--[@b37-ott-9-1499] the results are to some extent inconsistent, which may be due to the limitations in individual studies. In this study, we combined all the published case--control studies regarding the association between *APE1* Asp148Glu and urinary cancers to better explore this genetic variation on the risk of developing urinary cancers.

Materials and methods
=====================

Study identification and selection
----------------------------------

Case--control studies regarding the *APE1* Asp148Glu and the risk of urinary cancers published before September 12, 2015 were included through searches of PubMed and EMBASE by using the following terms and key words: "apurinic endonuclease" or "apyrimidinic endonuclease" or *APE1* or *APEX* or *APEX1* or *HAP1* or *REF-1*; polymorphism or variant or variation or mutation; and kidney or renal or urothelial or "transitional cell carcinoma" or bladder or prostatic or prostate. The search was limited to human studies. The criteria used for the study selection were as follows: 1) the articles were concerned about the association between *APE1* Asp148Glu and urinary cancers, including prostate cancer, kidney cancer, and bladder cancer; 2) the studies were designed as case--control studies; 3) detailed genotyping data were available; and 4) there were no overlapping data.

Data extraction
---------------

Information was carefully extracted from all the eligible studies independently by three investigators according to the selection criteria listed earlier. The following data were collected: first author's name, publication year, country, ethnicity (categorized as Asians, Caucasians, or the African--Americans), source of controls, genotyping method, numbers of cases and controls, genotype frequency of cases and controls, and the result of Hardy--Weinberg equilibrium (HWE) test. We did not require a minimum number of patients to be included in our meta-analysis.

Quality score assessment
------------------------

The study quality was assessed by using a quality assessment score developed for genetic association studies by Thakkinstian et al.[@b38-ott-9-1499] Total scores range from 0 (worst) to 12 (best). The criteria for quality assessment of genetic associations between the *APE1* Asp148Glu and urinary cancers are described in [Table S1](#SD1-ott-9-1499){ref-type="supplementary-material"}.

Statistical analysis
--------------------

Data in the control group were used to estimate a pooled allelic prevalence. HWE was tested by chi-squared test (*P*\<0.05 was considered representative of statistical significance). The minor allele frequency was also calculated for the controls. The strength of association between *APE1* Asp148Glu and the risk of urinary cancers was measured by odd ratios (ORs) with 95% confidence intervals (CIs). The pooled ORs were calculated for recessive model (Glu/Glu vs Asp/Glu+Asp/Asp), dominant model (Glu/Glu+Asp/Glu vs Asp/Asp), homozygote comparison (Glu/Glu vs Asp/Asp), heterozygote comparison (Asp/Glu vs Asp/Asp) and additive model (Glu vs Asp). Heterogeneity assumption was checked by a chi-square-based *Q* test, and *I*^2^ statistics was calculated to quantify the proportion of the total variation across studies due to heterogeneity.[@b39-ott-9-1499] A *P*-value of \>0.05 for the *Q* test indicated a lack of heterogeneity among studies, so that the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel--Haenszel method).[@b40-ott-9-1499] Otherwise, the random-effects model (the DerSimonian and Laird method) was used.[@b41-ott-9-1499] Subgroup analyses were conducted according to ethnicity (ie, Asians, African--Americans, Caucasians), cancer type (ie, all urinary cancers, kidney cancer, prostate cancer, and bladder cancer), genotyping methods (ie, polymerase chain reaction-restriction fragment length polymorphism \[PCR-RFLP\] and TaqMan), source of control (ie, population based and hospital based), and quality score (score \<7 or score ≥7). Sensitivity analyses were performed to test the reliability of results by sequential omission of individual studies.[@b42-ott-9-1499] Publication bias is the tendency on the parts of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings.[@b43-ott-9-1499] An estimate of potential publication bias was carried out by the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). Funnel plot asymmetry was further assessed by the method of Egger's linear regression test (*P*\<0.05 was considered a significant publication bias).[@b44-ott-9-1499] Statistical analyses were performed by using STATA statistical software (version 11.0).

Results
=======

Extraction process and study characteristics
--------------------------------------------

The selection process of the studies is presented in [Figure 1](#f1-ott-9-1499){ref-type="fig"}. In total, 419 potentially relevant articles were identified after the initial search, and 20 of them concentrated on the *APE1* Asp148Glu. Also, four additional articles were identified from retrieved articles. Thus, following implementation of our search criteria, we found 24 publications on the association between *APE1* Asp148Glu and the risk of urinary cancers.[@b10-ott-9-1499],[@b17-ott-9-1499],[@b19-ott-9-1499]--[@b28-ott-9-1499],[@b30-ott-9-1499]--[@b37-ott-9-1499],[@b45-ott-9-1499]--[@b48-ott-9-1499] Among them, eight studies were excluded because of duplicated data or lack of usable data.[@b10-ott-9-1499],[@b24-ott-9-1499],[@b26-ott-9-1499],[@b31-ott-9-1499],[@b35-ott-9-1499],[@b45-ott-9-1499],[@b46-ott-9-1499],[@b48-ott-9-1499] Because the two studies by Andrew et al[@b18-ott-9-1499],[@b25-ott-9-1499] contain overlapping data and the source of control in one of them[@b25-ott-9-1499] is mixed, the study by Andrew et al[@b18-ott-9-1499] was excluded when calculating the pooled OR, while the study by Andrew et al[@b25-ott-9-1499] was excluded when conducting the subgroup analysis according to the source of controls. Hence, 16 publications including 18 studies (5,539 cases and 7,348 controls) were selected in the meta-analysis. [Table 1](#t1-ott-9-1499){ref-type="table"} lists the studies identified and their main characteristics. Of them, there were ten bladder cancer studies, seven prostate cancer studies, and one kidney cancer study. There were six studies[@b32-ott-9-1499],[@b33-ott-9-1499],[@b36-ott-9-1499],[@b37-ott-9-1499],[@b47-ott-9-1499] involving Asians, ten studies with Caucasians,[@b17-ott-9-1499],[@b19-ott-9-1499]--[@b23-ott-9-1499],[@b25-ott-9-1499],[@b27-ott-9-1499],[@b28-ott-9-1499],[@b34-ott-9-1499] and two studies with African--Americans.[@b19-ott-9-1499],[@b30-ott-9-1499] The quality of all 18 studies ranged from 3 to 12, with a mean value of 6.9 (standard deviation: 2.18). The distribution of genotypes in the controls of each study was consistent with HWE except for two studies,[@b28-ott-9-1499],[@b34-ott-9-1499] which were not included in further pooling ([Table 2](#t2-ott-9-1499){ref-type="table"}). The pooled prevalence of the Glu were 0.424 (95% CI=0.393--0.456) in control group, while the pooled prevalence of the Glu among Asians were 0.383 (95% CI=0.311--0.456), Caucasians 0.467 (95% CI=0.454--0.480), and African--Americans 0.354 (95% CI=0.354--0.378).

Meta-analysis results
---------------------

[Table 3](#t3-ott-9-1499){ref-type="table"} lists the main results of the meta-analysis for *APE1* Asp148Glu. Overall, no significant association was found between Asp148Glu and the risk of urinary cancers (dominant model: OR=1.06, 95% CI=0.98--1.15; [Figure 2A](#f2-ott-9-1499){ref-type="fig"}). In the stratified analysis by ethnicity, we did not find significant associations among Caucasians (dominant model: OR=1.06, 95% CI=0.96--1.17; [Table 3](#t3-ott-9-1499){ref-type="table"}). Similarly, no significant associations were observed among the African--Americans (dominant model: OR=1.02, 95% CI=0.77--1.35; [Table 3](#t3-ott-9-1499){ref-type="table"}). However, among Asians, the individuals who carried the Glu/Glu genotype had an increased risk of urinary cancers (recessive model: OR=1.26, 95% CI=1.03--1.54, *P*=0.022; [Table 3](#t3-ott-9-1499){ref-type="table"}, [Figure 2B](#f2-ott-9-1499){ref-type="fig"}). When stratified by the source of controls, no significant associations were found in both population-based studies and hospital-based studies ([Table 3](#t3-ott-9-1499){ref-type="table"}). When stratified by the quality score, no significant association was found in high-quality studies (score ≥7), but a significant increased risk of urinary cancers was observed in lower quality studies (score \<7) (dominant model: OR=1.27, 95% CI=1.11--1.45). Subgroup analyses based on cancer type also showed that there was no significant association of bladder cancer. However, significant association was found between Asp148Glu and the risk of prostate cancer (dominant model: OR=1.21, 95% CI=1.03--1.42, [Figure 3A](#f3-ott-9-1499){ref-type="fig"}; heterozygote comparison: OR=1.12, 95% CI=1.03--1.44, [Figure 3B](#f3-ott-9-1499){ref-type="fig"}; additive model: OR=1.12, 95% CI=1.00--1.26). Meanwhile, a significant increased risk of prostate cancer was observed among Caucasians (dominant model: OR=1.45, 95% CI=1.08--1.94; heterozygote comparison: OR=1.44, 95% CI=1.06--1.94; additive model: OR=1.26, 95% CI=1.02--1.56) and Asians (homozygote comparison: OR=1.61, 95% CI=1.05--2.46) but not African--Americans.

Test of heterogeneity and sensitivity analyses
----------------------------------------------

The heterogeneity test showed that there was no significant heterogeneity in overall comparisons ([Table 3](#t3-ott-9-1499){ref-type="table"}). Although the genotype distributions in two studies[@b28-ott-9-1499],[@b34-ott-9-1499] did not follow the HWE, the corresponding pooled ORs were not materially altered by including or excluding the studies. Additionally, we also assessed the influence of each individual study on the pooled ORs by sequential omission of individual studies. The results showed that the pooled ORs of this polymorphism were altered by omission of the study by Figueroa et al[@b23-ott-9-1499] ([Figure 4](#f4-ott-9-1499){ref-type="fig"}).

Publication bias
----------------

Begg's funnel plot and Egger's test were conducted to estimate the publication bias of studies. It was showed that Egger's test was significant for publication bias in heterozygote comparison (*P*\<0.001), additive model (*P*=0.04), and dominant model (*P*=0.001). However, the Egger's test was not statistically significant for publication bias in recessive model (*P*=0.893) and homozygote comparison (*P*=0.237). It suggested that a possibility of publication bias could have existed in the studies.

Discussion
==========

Numerous epidemiological studies have been conducted to explore the association between *APE1* Asp148Glu and the risk of urinary cancers.~17,19--23,25,27,28,30--34,36,37~ However, the results are to some extent inconsistent, which may be due to the limitations in individual studies. Meta-analysis has been widely used in epidemiological research, especially for evaluating genetic polymorphisms in cancer susceptibility. It can improve statistical power, subsequently drawing a more reliable conclusion.[@b49-ott-9-1499] Therefore, we performed a meta-analysis to explore the association between *APE1* Asp148Glu and the risk of urinary cancers. Our results indicated that the individuals who carried the Glu/Glu genotype have an increased risk of urinary cancers among Asians. Meanwhile, significant association was found between Asp148Glu and the risk of prostate cancer.

Several genome-wide association studies have identified susceptibility variants,[@b50-ott-9-1499]--[@b52-ott-9-1499] providing evidence in support of the role of genetic susceptibility in developing urinary cancers. As for prostate cancer, the prostate carcinogenesis is a result of multiple environmental and hereditary risk factors, and genetic factors play important roles in the development of prostate cancer.[@b53-ott-9-1499] Functional studies on *APE1* Asp148Glu suggested that the Glu may alter endonuclease and DNA-binding activity, reduce the ability to communicate with other BER proteins, and decrease the capacity to repair DNA oxidative damage.[@b15-ott-9-1499] In the study on X-ray exposure to lymphocytes and polymorphisms of DNA repair genes on chromosome aberrations, samples from individuals with the Asp/Glu or Glu/Glu genotype showed higher levels of damage with regard to all the studied measures, including aberrant cells, chromatid breaks, chromatid exchanges, deletions, and dicentrics.[@b16-ott-9-1499]

The combined results based on all the studies showed that no significant association was found between Asp148Glu and the risk of urinary cancers. Meanwhile, no significant associations were observed among Caucasians and African--Americans. However, a significant association was found among Asians. The discrepancy suggested a possible role of ethnic difference in genetic background and the environment. The same polymorphisms play different roles in cancer susceptibility among different ethnic populations, because cancer is a complicated multi-genetic disease, and different genetic background may contribute to the discrepancy.[@b54-ott-9-1499] Meanwhile, when stratified by the quality score, no significant association was found in high-quality studies (score ≥7) but a significant increased risk of urinary cancers risk was observed in lower quality studies (score \<7). The combined results based on all the high-quality studies further supported the previous conclusion that no significant association was found between Asp148Glu and the risk of urinary cancers.

One recent meta-analysis by Liu et al[@b46-ott-9-1499] estimated the association between Asp148Glu and the risk of bladder cancer, which was basically in accordance with our opinion that Asp148Glu may not contribute to the susceptibility to bladder cancer. However, another published meta-analysis by Zhou et al[@b48-ott-9-1499] showed that no significant association was found between Asp148Glu and the risk of prostate cancer, which is contrast with our results. One possible explanation of the contrast may be that different studies were included in the meta-analysis. As shown in the selection process of the studies, we mentioned that the studies by Mandal et al[@b35-ott-9-1499] and Mittal et al[@b36-ott-9-1499] were reported from the same organization. Actually, these two studies may contain partial overlapping data when carefully reading the full texts, and only the larger study[@b36-ott-9-1499] should be selected for the analysis. However, the meta-analysis by Zhou et al[@b48-ott-9-1499] included the studies by Mandal et al[@b35-ott-9-1499] and Mittal et al,[@b36-ott-9-1499] which might be biased by not taking into account the effects of overlapping data. Meanwhile, the study by Zhou et al[@b48-ott-9-1499] was not included in the previous meta-analysis. Thus, the results of our meta-analysis are more accurate and reliable. However, in our meta-analysis, only two or three studies on prostate cancer were available for each specific ethnicity, and they had limited sample size; hence, larger studies are needed to explore the association between Asp148Glu and prostate cancer risk among Africans, Asians, and Caucasians.

Some limitations of our meta-analysis should be considered. First, the number of published studies included in our meta-analysis was not large enough for subgroup analyses by ethnicity and cancer type. Second, our results were unadjusted estimates because of lack of detailed data, such as age, sex, and environmental factors in the studies included. Third, some inevitable publication bias might exist in the results because only published studies were available to be included.

Conclusion
==========

Our meta-analysis suggests that Asp148Glu was not associated with the risk of urinary cancers but might increase the risk of urinary cancers among Asians. Stratification by cancer type identified a significant association of Asp148Glu with prostate cancer. Additional larger studies, stratified by gene--gene and gene--environmental interactions, are needed to further explore the association between Asp148Glu and the susceptibility to urinary cancers.

Supplementary material
======================

###### 

Criteria for quality assessment of genetic associations of the *APE1* Asp148Glu polymorphism with the risk of urinary cancers

  Criteria                                                                                                                          Quality score
  --------------------------------------------------------------------------------------------------------------------------------- ---------------
  **Representativeness of cases**                                                                                                   
  A. Consecutive/randomly selected from case population with clearly defined random frame                                           2
  B. Consecutive/randomly selected from case population without clearly defined random frame or with extensive inclusion criteria   1
  C. Method of selection not described                                                                                              0
  **Representativeness of controls**                                                                                                
  D. Controls were consecutive/randomly drawn from the same area (ward/community) as cases with the same criteria                   2
  E. Controls were consecutive/randomly drawn from a different area than cases                                                      1
  F. Not described                                                                                                                  0
  **Ascertainment of cancer cases**                                                                                                 
  G. Clearly described objective criteria for diagnosis of cancer                                                                   1
  H. Not described                                                                                                                  0
  **Ascertainment of controls**                                                                                                     
  I. Clinical examinations were performed on controls to prove that controls did not have cancer                                    2
  J. Article merely stated that controls were subjects who did not have cancer; no proof provided                                   1
  K. Not described                                                                                                                  0
  **Ascertainment of genotyping examination**                                                                                       
  L. Genotyping done under "blind" conditions                                                                                       1
  M. Unblended or not mentioned                                                                                                     0
  **Test for Hardy--Weinberg equilibrium**                                                                                          
  N. Hardy--Weinberg equilibrium in control group                                                                                   2
  O. Hardy--Weinberg disequilibrium in control group                                                                                1
  P. Hardy--Weinberg equilibrium not checked                                                                                        0
  **Association assessment**                                                                                                        
  Q. Assessed association between genotypes and cancer with appropriate statistic and adjusting confounders                         2
  R. Assessed association between genotypes and cancer with appropriate statistic without adjusting confounders                     1
  S. Inappropriate statistic used                                                                                                   0
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![Flow diagram of the studies included in this meta-analysis.](ott-9-1499Fig1){#f1-ott-9-1499}

![Forest plots of ORs with 95% CI for *APE1* Asp148Glu and the risk of urinary cancers observed in subgroup analyses by ethnicity (fixed effects).\
**Notes:** The center of each square represents the OR, the area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI. (**A**) Dominant model and (**B**) recessive model.\
**Abbreviations:** CI, confidence interval; ORs, odds ratios.](ott-9-1499Fig2){#f2-ott-9-1499}

###### 

Forest plot of ORs with 95% CI for *APE1* Asp148Glu and the risk of prostate cancer in subgroup analyses by ethnicity (fixed effects).

**Notes:** The center of each square represents the OR, the area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI. (**A**) Dominant model and (**B**) heterozygote comparison.

**Abbreviations:** CI, confidence interval; ORs, odds ratios.
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![Sensitivity analyses for the robustness of association between *APE1* polymorphism and the risk of urinary cancers.\
**Note:** The vertical line corresponds to the combined relative risk from the fixed effects model.\
**Abbreviation:** CI, confidence interval.](ott-9-1499Fig4){#f4-ott-9-1499}

###### 

Characteristics of studies included in the meta-analysis

  Author                               Year   Quality score   Ethnicity   Region                       Cancer type   Genotyping                Control source   Cases/controls
  ------------------------------------ ------ --------------- ----------- ---------------------------- ------------- ------------------------- ---------------- ----------------
  Broberg et al[@b17-ott-9-1499]       2005   6               Caucasian   Sweden                       BC            TaqMan                    PB               61/155
  Matullo et al[@b20-ott-9-1499]       2006   3               Caucasian   Multiple countries           BC            TaqMan                    PB               124/1,094
  Wu et al[@b22-ott-9-1499]            2006   9               Caucasian   USA                          BC            TaqMan                    HB               596/590
  Terry et al[@b21-ott-9-1499]         2006   6               Caucasian   USA                          BC            MALDI--TOF                HB               229/207
  Chen et al[@b19-ott-9-1499]          2006   6               Caucasian   USA                          PCa           PCR-RFLP                  HB               228/217
  Chen et al[@b19-ott-9-1499]          2006   6               African     USA                          PCa           PCR-RFLP                  HB               123/112
  Figueroa et al[@b23-ott-9-1499]      2007   7               Caucasian   Spain                        BC            TaqMan                    HB               1,094/1,013
  Andrew et al[@b25-ott-9-1499]        2008   8               Caucasian   USA/Italy                    BC            SNP mass-tagging system   Mixed            911/1,165
  Michiels et al[@b27-ott-9-1499]      2009   10              Caucasian   France                       BC            Illumina                  HB               189/316
  Narter et al[@b28-ott-9-1499]        2009   4               Caucasian   Turkey                       BC            PCR-RFLP                  NR               75/35
  Wang et al[@b32-ott-9-1499]          2010   6               Asian       People's Republic of China   BC            PCR-RFLP                  HB               234/253
  Lavender et al[@b30-ott-9-1499]      2010   10              African     USA                          PCa           TaqMan                    HB               186/631
  Cao et al[@b33-ott-9-1499]           2011   6               Asian       People's Republic of China   KC            TaqMan                    HB               612/632
  Kuasne et al[@b34-ott-9-1499]        2011   4               Caucasian   Brazil                       PCa           PCR-RFLP                  HB               172/172
  Mittal et al[@b36-ott-9-1499]        2012   9               Asian       India                        BC            PCR-RFLP and ARMS         PB               212/250
  Mittal et al[@b36-ott-9-1499]        2012   9               Asian       India                        PCa           PCR-RFLP and ARMS         PB               195/250
  Jing et al[@b37-ott-9-1499]          2013   10              Asian       People's Republic of China   PCa           PCR-RFLP                  HB               198/156
  Pournourali et al[@b47-ott-9-1499]   2015   6               Asian       Iran                         PCa           PCR-RFLP                  HB               100/100

**Abbreviations:** SNP, single nucleotide polymorphism; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; TaqMan, real-time TaqMan analysis; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; ARMS, amplification refractory mutation specific; BC, bladder cancer; PCa, prostate cancer; KC, kidney cancer; PB, population based; HB, hospital based.

###### 

Genotype distribution of *APE1* Asp148Glu used in the meta-analysis

  References                           Year   Ethnicity   Cancer type   Control source   Sample size (case/control)   Case (genotype %)   Control (genotype %)   HWE   MAF                            
  ------------------------------------ ------ ----------- ------------- ---------------- ---------------------------- ------------------- ---------------------- ----- ----- ----- ----- ----- ------ ------
  Broberg et al[@b17-ott-9-1499]       2005   Caucasian   BC            PB               61                           155                 9                      35    17    37    79    39    0.81   0.51
  Matullo et al[@b20-ott-9-1499]       2006   Caucasian   BC            PB               124                          1,094               31                     69    24    309   526   259   0.23   0.48
  Wu et al[@b22-ott-9-1499]            2006   Caucasian   BC            HB               596                          590                 176                    283   137   166   279   145   0.20   0.48
  Terry et al[@b21-ott-9-1499]         2006   Caucasian   BC            HB               229                          207                 51                     133   45    63    104   40    0.80   0.44
  Chen et al[@b19-ott-9-1499]          2006   Caucasian   PCa           HB               228                          217                 65                     122   41    73    108   36    0.71   0.41
  Chen et al[@b19-ott-9-1499]          2006   African     PCa           HB               123                          112                 42                     64    17    42    59    11    0.14   0.36
  Figueroa et al[@b23-ott-9-1499]      2007   Caucasian   BC            HB               1,094                        1,013               335                    510   249   292   491   230   0.39   0.47
  Andrew et al[@b25-ott-9-1499]        2008   Caucasian   BC            Mixed            911                          1,165               259                    461   191   333   586   246   0.69   0.46
  Michiels et al[@b27-ott-9-1499]      2009   Caucasian   BC            HB               189                          316                 53                     96    40    94    154   68    0.74   0.46
  Narter et al[@b28-ott-9-1499]        2009   Caucasian   BC            NR               75                           35                  50                     14    11    27    4     4     0.00   0.17
  Wang et al[@b32-ott-9-1499]          2010   Asian       BC            HB               234                          253                 78                     116   40    84    129   40    0.41   0.41
  Lavender et al[@b30-ott-9-1499]      2010   African     PCa           HB               186                          631                 82                     88    16    274   269   88    0.10   0.35
  Cao et al[@b33-ott-9-1499]           2011   Asian       KC            HB               612                          632                 181                    292   139   199   329   104   0.10   0.43
  Kuasne et al[@b34-ott-9-1499]        2011   Caucasian   PCa           HB               172                          172                 84                     83    5     106   64    2     0.02   0.20
  Mittal et al[@b36-ott-9-1499]        2012   Asian       BC            PB               212                          250                 126                    82    4     141   92    17    0.71   0.25
  Mittal et al[@b36-ott-9-1499]        2012   Asian       PCa           PB               195                          250                 108                    72    15    136   101   13    0.30   0.25
  Jing et al[@b37-ott-9-1499]          2013   Asian       PCa           HB               198                          156                 66                     98    34    60    73    23    0.92   0.38
  Pournourali et al[@b47-ott-9-1499]   2015   Asian       PCa           HB               100                          100                 15                     60    25    30    50    20    0.92   0.45

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; A, major allele; a, minor allele; BC, bladder cancer; PCa, prostate cancer; KC, kidney cancer; PB, population based; HB, hospital based.

###### 

Stratified analyses of Asp148Glu on the risk of urinary cancers

  Genetic model       Recessive model    Dominant model      Homozygote   Heterozygote   Additive model                                                                                                                       
  ------------------- ------------------ ------------------- ------------ -------------- ------------------- ------- ------ ------------------- ------- ------ ------------------- ------- ------ ------------------- ------- ------
  **UC**              18 (5,539/7,348)   1.03 (0.94--1.13)   0.148        26.2           1.06 (0.98--1.15)   0.176   23.5   1.06 (0.95--1.19)   0.072   34.9   1.07 (0.98--1.16)   0.236   18.2   1.04 (0.98--1.09)   0.173   23.8
  Ethnicity                                                                                                                                                                                                                   
   Caucasian          10 (3,679/4,964)   0.98 (0.88--1.10)   0.952        0              1.06 (0.96--1.17)   0.105   37.9   1.02 (0.89--1.16)   0.678   0      1.08 (0.97--1.19)   0.120   36.0   1.02 (0.96--1.09)   0.303   15.3
   Asian              6 (1,551/1,641)    1.26 (1.03--1.54)   0.085        48.3           1.08 (0.93--1.25)   0.197   31.8   1.25 (0.84--1.84)   0.047   55.5   1.03 (0.89--1.21)   0.260   23.2   1.10 (1.00--1.22)   0.169   35.7
   African            2 (309/743)        0.77 (0.50--1.20)   0.063        71.1           1.02 (0.77--1.35)   0.589   0      1.06 (0.95--1.19)   0.081   67.1   1.09 (0.81--1.46)   0.982   0      0.95 (0.78--1.09)   0.203   38.3
  Source of control                                                                                                                                                                                                           
   PB                 4 (592/1,749)      0.85 (0.67--1.07)   0.114        46.4           1.00 (0.84--1.19)   0.500   0      0.90 (0.69--1.17)   0.079   52.2   1.05 (0.87, 1.26)   0.482   0      0.96 (0.85--1.08)   0.484   0
   HB                 12 (3,961/4,399)   1.06 (0.95--1.19)   0.233        21.5           1.08 (0.98--1.19)   0.089   37.9   1.09 (0.96--1.24)   0.099   36.5   1.07 (0.97, 1.18)   0.127   33.0   1.05 (0.99--1.12)   0.113   34.6
  Quality score                                                                                                                                                                                                               
   ≥7                 8 (3,581/4,371)    0.95 (0.85--1.07)   0.152        34.6           0.97 (0.88--1.07)   0.933   0      1.06 (0.95--1.19)   0.072   34.9   0.99 (0.98--1.16)   0.929   0      0.97 (0.91--1.04)   0.173   23.8
   \<7                10 (1,958/2,977)   1.20 (1.02--1.41)   0.580        0              1.27 (1.11--1.45)   0.341   11.1   1.37 (1.14--1.66)   0.718   0      1.23 (1.07--1.42)   0.197   26.8   1.17 (1.07--1.28)   0.646   0
  **BC**              10 (3,725/5,078)   0.96 (0.86--1.07)   0.598        0              1.01 (0.92--1.11)   0.407   3.6    0.98 (0.86--1.11)   0.386   6.0    1.03 (0.93--1.14)   0.392   5.3    0.99 (0.93--1.06)   0.636   0
  Ethnicity                                                                                                                                                                                                                   
   Caucasian          8 (3,279/4,575)    0.97 (0.87--1.09)   0.972        0              1.02 (0.92--1.14)   0.269   20.3   0.99 (0.87--1.14)   0.772   0      1.04 (0.93--1.16)   0.226   25.4   1.00 (0.94--1.07)   0.657   0
   Asian              2 (446/503)        0.59 (0.15--2.37)   0.020        81.7           0.94 (0.72--1.22)   0.660   0      0.58 (0.15--2.30)   0.025   80.1   0.98 (0.75--1.30)   0.916   0      0.93 (0.76--1.13)   0.226   31.8
  Source of control                                                                                                                                                                                                           
   PB                 3 (397/1,499)      0.80 (0.63--1.02)   0.161        41.8           1.01 (0.83--1.23)   0.347   9.2    0.84 (0.63--1.12)   0.077   56.2   1.09 (0.89--1.34)   0.433   0      0.94 (0.83--1.07)   0.347   3.7
   HB                 5 (2,342/2,379)    0.99 (0.86--1.13)   0.970        0              0.99 (0.87--1.12)   0.292   19.3   0.98 (0.83--1.15)   0.718   0      0.99 (0.91--1.14)   0.262   23.9   0.99 (0.91--1.07)   0.655   0
  **PCa**             7 (1,202/1,638)    1.08 (0.85--1.38)   0.270        21.0           1.21 (1.03--1.42)   0.155   35.8   1.23 (0.94--1.61)   0.127   39.7   1.12 (1.03--1.44)   0.236   25.3   1.12 (1.00--1.26)   0.177   32.9
  Ethnicity                                                                                                                                                                                                                   
   Caucasian          2 (400/389)        1.19 (0.74--1.90)   0.342        0              1.45 (1.08--1.94)   0.350   0      1.42 (0.84--2.39)   0.313   1.7    1.44 (1.06--1.94)   0.410   0      1.26 (1.02--1.56)   0.225   32.0
   Asian              3 (493/506)        1.31 (0.90--1.92)   0.889        0              1.21 (0.93--1.58)   0.070   62.4   1.61 (1.05--2.46)   0.497   0      1.16 (0.88--1.53)   0.063   63.9   1.18 (0.98--1.43)   0.359   2.3
   African            2 (309/743)        0.77 (0.50--1.20)   0.063        71.1           1.02 (0.77--1.35)   0.589   0      0.80 (0.50--1.29)   0.081   67.1   1.09 (0.81--1.46)   0.982   0      0.95 (0.78--1.17)   0.203   38.3
  Source of control                                                                                                                                                                                                           
   PB                 1 (195/250)        1.52 (0.71--3.27)   --           --             0.96 (0.66--1.40)   --      --     1.45 (0.66--3.18)   --      --     0.90 (0.61--1.33)   --      --     1.04 (0.77--1.41)   --      --
   HB                 6 (1,007/1,388)    1.04 (0.81--1.34)   0.234        26.7           1.27 (1.07--1.52)   0.179   34.3   1.20 (0.91--1.60)   0.081   48.9   1.30 (1.08--1.56)   0.381   5.6    1.14 (1.01--1.29)   0.124   42.1

**Notes:** *P*~h~, *P*-values for heterogeneity from *Q* test. Random-effects model was used when *P*-value for heterogeneity test was less than 0.05, otherwise, fixed-effects model was used.

N= numbers of comparisons and the sample size (case/control).

**Abbreviations:** UC, urinary cancers; BC, bladder cancer; PCa, prostate cancer; PB, population based; HB, hospital based.

[^1]: These authors contributed equally to this work
